A Clinical Observation on Supplemented Yiguan Brew Combined with Transcatheter Hepatic Arterial Chemo-Embolization for 42 Cases of Primary Liver Cancer

LU Yiqiong; LI Huabo

doi:10.13288/j.11-2166/r.2013.05.029

您当前的位置：

首页 >

文章列表页 >

A Clinical Observation on Supplemented Yiguan Brew Combined with Transcatheter Hepatic Arterial Chemo-Embolization for 42 Cases of Primary Liver Cancer

更新时间：2021-11-17

- A Clinical Observation on Supplemented Yiguan Brew Combined with Transcatheter Hepatic Arterial Chemo-Embolization for 42 Cases of Primary Liver Cancer
- Journal of Traditional Chinese Medicine Vol. 54, Issue 5, Pages: 405-408(2013)
- 作者机构：
  
  湖北民族学院附属民大医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2013.05.029
  CLC： R735.7
- Published：2013
- 稿件说明：
移动端阅览
[1]卢义琼,李华波.加味一贯煎联合经导管肝动脉栓塞术治疗原发性肝癌42例临床研究[J].中医杂志,2013,54(05):405-408.

LU Yiqiong, LI Huabo. A Clinical Observation on Supplemented Yiguan Brew Combined with Transcatheter Hepatic Arterial Chemo-Embolization for 42 Cases of Primary Liver Cancer[J]. Journal of Traditional Chinese Medicine2013, 54(5): 405-408.
[1]卢义琼,李华波.加味一贯煎联合经导管肝动脉栓塞术治疗原发性肝癌42例临床研究[J].中医杂志,2013,54(05):405-408. DOI： 10.13288/j.11-2166/r.2013.05.029.

LU Yiqiong, LI Huabo. A Clinical Observation on Supplemented Yiguan Brew Combined with Transcatheter Hepatic Arterial Chemo-Embolization for 42 Cases of Primary Liver Cancer[J]. Journal of Traditional Chinese Medicine2013, 54(5): 405-408. DOI： 10.13288/j.11-2166/r.2013.05.029.

摘要

目的观察加味一贯煎联合经导管肝动脉栓塞术（TACE）治疗原发性肝癌的临床疗效。方法将中晚期原发性肝癌患者80例随机分为试验组42例和对照组38例

试验组采用加味一贯煎联合TACE治疗;对照组采用单纯TACE治疗。TACE后16周评价两组患者临床疗效

并于TACE前后检测患者血清甲胎蛋白（AFP）水平、肝功能、卡氏评分和血氧饱和度（SaO2）水平

同时观察患者不良反应。结果试验组总缓解率57.14%

对照组为47.37%

两组比较差异有统计学意义（P<0.05）。两组患者TACE后血清AFP水平较TACE前均下降（P<0.05）;试验组TACE后第21、28天血清AFP水平显著低于对照组（P<0.05）。两组患者TACE后第3天肝功能各指标较TACE前均升高（P<0.05）

试验组各指标在第28、84天均接近TACE前水平（P>0.05）

对照组在第28、84天各项指标均明显高于TACE前水平（P<0.05）

试验组患者TACE后肝功能各指标均明显低于同期对照组（P<0.05）。两组患者TACE后卡氏评分和SaO2水平均较TACE前提高（P<0.05）

TACE后试验组卡氏评分明显高于对照组（P<0.05）。试验组不良反应发生率低于对照组（P<0.05）。结论加味一贯煎联合TACE治疗原发性肝癌临床疗效显著

能提高TACE的治疗效率并减少并发症及不良反应。

Abstract

Objective To observe the therapeutic effect of Supplemented Yiguan Brew （All-the-Way-Through Brew） combined with transcatheter hepatic arterial chemo-embolization （TACE） on primary liver cancer.Methods Eighty cases of advanced primary liver cancer were divided into the test group of 42 cases and control group of 38 cases according to the register number. Both groups were given TACE and Supplemented Yiguan Brew was added in the test group. The therapeutic effect was evaluated 16 weeks later. The serum alpha-fetoprotein （AFP） levels

liver function

Karnofsky scores

SaO2 levels and side effects in both groups were observed.Results The total remission rate in the test group and control group was 57.14% and 47.37% respectively

with a significant difference between groups （P<0.05）. The AFP levels in both groups were significantly decreased （P<0.05）. The AFP levels in the test group were significantly lower than those in the control group on the 21st and 28th day after TACE （P<0.05）. The liver function improved in both groups on the 3rd day after TACE （P<0.05）. The indicators of liver function on the 28th and 84th day were closed to those before TACE in the test group （P>0.05）. The indicators of liver function on the 28th and 84th day were significantly higher than those before TACE in the control group （P<0.05）. The indicators of liver function in the test group were significantly lower than those in the control group at the same time point after TACE （P<0.05）. The Karnofsky scores and SaO2 levels were significantly increased in both groups after TACE （P<0.05）. The Karnofsky score in the test group was significantly higher than that in the control group after TACE （P<0.05）. The incidence of side effect in the test group was significantly lower than that in the control group （P<0.05）.Conclusion Supplemented Yiguan Brew combined with TACE is effective for primary liver cancer with better efficacy

lower complications and less side effect.

关键词

Keywords

references

查看原文

Views

219

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Combined with Western Medicine Therapy in the Treatment of 80 Cases of Hepatitis B Related Primary Liver Cancer with the Syndrome of Deficiency of Qi and Yin, and Acummulation of Toxin and Stasis

Effects of Huqi Formula（槲芪方） on Quality of Life of Primary Liver Cancer of Vital Qi Deficiency and Toxin-Blood Stasis Coagulation Syndrom: A Retrospective Cohort Study

Pathomechanism and Treatment Strategy of Phlegm and Blood Stasis in the Immunosuppressive Tumor Microenvironment of Liver Cancer

Effect of Shipi Xiaoji Beverage（实脾消积饮）-containing Serum on Mitochondrial Dynamics Imbalance and Ferroptosis of Liver Cancer HepG2 Cells

The Effects of Huqi Zhengxiao Formula （槲芪癥消方） on the Survival Rate and Quality of Life of Patients of Stage Ⅲ Hepatitis B-Associated Primary Liver Cancer with Syndrome of Healthy Qi Deficiency， Toxic Stasis Accumulation After Transcatheter Arterial Chemoembolisation Treatment

Related Author

LIU Huimin

WANG Xinhui

LIU Xiaoli

SHI Ke

LI Yuxin

JIANG Yuyong

WANG Xianbo

ZHANG Liang

Related Institution

Beijing Ditan Hospital,Capital Medical University

Shanxi Medical University

Beijing Institute of Liver Disease,Beijing You’an Hospital,Capital Medical University

Beijing You’an Hospital,Capital Medical University

Third Affiliated Hospital of Beijing University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰